Hematologic imaging Book Section


Author: Mayerhoefer, M. E.
Editor: Catalano, O. A.
Article/Chapter Title: Hematologic imaging
Abstract: Blood cancers are among the malignancies for which hybrid imaging is most frequently used. Current guidelines recommend [18F]Fluorodeoxyglucose (FDG)-positron emission tomography (PET) for staging and treatment response assessment in most cases. However, some indolent non-Hodgkin lymphomas such as marginal zone lymphomas small lymphocytic lymphoma/chronic lymphocytic leukemia show variable, sometimes very low FDG uptake. Here, PET/magnetic resonance imaging (MRI) seems to outperform PET/CT, because diffusion-weighted imaging (DWI) is highly sensitive for lymphomas. In myelomas, FDG-PET is also recommended by current guidelines, although >10% of cases are non-FDG-avid. Given that MRI, and in particular DWI, are well established for myeloma evaluation, and especially diffuse marrow infiltration, PET/MRI may be a logical choice, although currently not officially endorsed. A promising novel PET tracer in blood cancers—including non-FDG-avid lymphomas and precursor myeloma—is [68Ga]Pentixafor, which targets CXCR4, a chemokine with a key function for cell migration. © 2023 Elsevier Inc. All rights reserved.
Keywords: staging; lymphoma; response; pet; mri; myeloma
Book Title: Clinical PET/MRI
ISBN: 978-0-323-88537-9
Publisher: Academic Press  
Publication Place: London, United Kingdom
Date Published: 2022-01-01
Start Page: 225
End Page: 244
Language: English
DOI: 10.1016/b978-0-323-88537-9.00016-7
PROVIDER: scopus
DOI/URL:
Notes: Book Chapter: 9 -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors